Literature DB >> 9624213

Genetically modified tumor cell vaccines.

F S Hodi1, G Dranoff.   

Abstract

Recent progress in identifying tumor antigens and understanding the host-tumor relationship have catalyzed a dramatic expansion of efforts to develop cancer vaccines. Gene transfer technologies have figured prominently in the design of many of these novel immunization schemes. This article highlights some of the key principles and controversies raised by experiments involving genetically modified tumor vaccines and speculates about future directions for investigators in this field.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624213

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

Review 1.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

2.  Long-term immunological memory in the resistance of rats to transplanted intracerebral 9L gliosarcoma (9LGS) following subcutaneous immunization with 9LGS cells.

Authors:  H M Smilowitz; D D Joel; D N Slatkin; P L Micca; M M Nawrocky; K Youngs; W Tu; J A Coderre
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

3.  The combination of boron neutron-capture therapy and immunoprophylaxis for advanced intracerebral gliosarcomas in rats.

Authors:  H M Smilowitz; P L Micca; M M Nawrocky; D N Slatkin; W Tu; J A Coderre
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

4.  The combination of X-ray-mediated radiosurgery and gene-mediated immunoprophylaxis for advanced intracerebral gliosarcomas in rats.

Authors:  H M Smilowitz; J A Coderre; M M Nawrocky; W Tu; A Pinkerton; G H Jahng; N Gebbers; D N Slatkin
Journal:  J Neurooncol       Date:  2002-03       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.